NCAM1: Neural cell adhesion molecule 1
This protein is a cell adhesion molecule involved in neuron- neuron adhesion, neurite fasciculation, outgrowth of neurites, etc.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on NCAM1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody-drug conjugate 1
- Other 1
| Lorvotuzumab mertansine | Phase 2 | AbbVie | Antibody-drug conjugate | Binding agentNeural cell adhesion molecule 1 binding agent | 0 |
| Oncolysin s | Phase 2 | — | Other | Binding agentNeural cell adhesion molecule 1 binding agent | 0 |
- Major depressive disorder0.53
- Smoking initiation0.50
- Gastroesophageal reflux disease0.50
- Schizophrenia0.46
- Irritable bowel syndrome0.46
- Abdominal pain0.45
- Back pain0.43
- Depressive disorder0.43
- Mood disorder0.43
- Neuropathic pain0.43
- Musculoskeletal system disorder0.42
- Chronic pain0.42
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712938, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P13591, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets